---
title: 'Cyst‑X Dataset: Overview & Benchmarks'
url: https://www.emergentmind.com/topics/cyst-x-dataset
type: topic
---

# Cyst‑X Dataset: Overview & Benchmarks

The designation **Cyst‑X Dataset** does not denote a single, universally fixed benchmark across the arXiv literature. Instead, it is used for multiple cyst-related imaging resources in different subfields. In pancreatic imaging, later literature and project materials refer to a 2017 abdominal CT collection for pancreas and pancreatic cyst segmentation as **Cyst‑X** [1706.07346]. In ophthalmic imaging, the OCT community uses **Cyst‑X** or **OPTIMA Cyst‑X** for the MICCAI 2015 OPTIMA cyst segmentation challenge dataset for intraretinal cysts [1708.06197; 2604.10843]. In 2025, **Cyst‑X** became the formal name of a publicly released multicenter pancreatic MRI dataset for intraductal papillary mucinous neoplasm (IPMN) malignancy prediction and federated learning [2507.22017]. A practical implication is that references to “Cyst‑X” are underspecified unless the imaging modality, anatomy, and task are stated explicitly.

## 1. Terminology and scope

In the literature summarized here, **Cyst‑X** is a reused label rather than a unique canonical dataset name. The ambiguity is historically understandable: earlier authors introduced cyst-focused datasets without formal names, and later papers or project pages attached the shorthand retrospectively; the 2025 pancreatic MRI release then formalized **Cyst‑X** as an official dataset name [1706.07346; 2507.22017].

| Usage in literature | Modality and domain | Core content |
|---|---|---|
| Later-named pancreatic **Cyst‑X** | Contrast-enhanced abdominal CT | 131 pathological samples with pancreas and cyst masks |
| **OPTIMA / OCSC / Cyst‑X** | Multi-vendor SD-OCT | 30 OCT volumes with dual-grader retinal cyst annotations |
| Formal **Cyst‑X** release | Multicenter pancreatic MRI | 1,461 MRI volumes from 764 patients with pancreas masks and IPMN risk labels |

This naming overlap matters because the three resources differ not only in modality but also in supervision granularity, target anatomy, and benchmark objective. The CT resource is a 3D lesion segmentation dataset; the OCT resource is a multi-vendor retinal cyst segmentation challenge; the MRI resource is primarily a pancreas-segmentation and malignancy-risk-classification benchmark [1706.07346; 1708.06197; 2507.22017].

## 2. The pancreatic CT resource later referred to as Cyst‑X

The 2017 paper on pancreatic cyst segmentation introduced a **new dataset with 131 pathological samples**, described as **131 contrast-enhanced abdominal CT volumes** with **cystic pancreata** [1706.07346]. The paper itself did not assign a formal dataset name, but later literature and the project webpage often referred to it as the **Cyst‑X dataset**. Each volume has in-plane resolution **512 × 512**, slice count **\(L \in [358, 1121]\)**, and **0.5 mm – 1.0 mm** slice thickness. Every case is manually labeled with both **pancreas segmentation \(\mathbf{P}^\star\)** and **cyst segmentation \(\mathbf{C}^\star\)**, giving voxel-level 3D supervision for organ and lesion.

The dataset encodes a strong anatomical prior: in **121 out of 131 cases**, more than **95%** of cyst voxels lie within the pancreas volume,
$$
\frac{|\mathcal{P}^\star \cap \mathcal{C}^\star|}{|\mathcal{C}^\star|} > 95\%.
$$
This relation underpins the paper’s two-stage design, in which pancreas localization guides cyst segmentation. The class imbalance is severe: the pancreas occupies **<1%** of voxels in a CT volume, while the **cyst fraction is often much smaller than 0.1%** and can be approximately **0.0015% of the entire volume**, or about **1.5% of the pancreas**.

The benchmark protocol uses **4 fixed folds** with **4-fold cross-validation**. The model slices each 3D CT along **coronal**, **sagittal**, and **axial** directions and trains a **2D FCN-8s** based on **VGG-16**, initialized from **Pascal VOC** segmentation weights. For cyst segmentation, the input is transformed by masking around the pancreas prediction with a distance threshold **\(t = 15\)** voxels. The principal metric is the **Dice-Sørensen Coefficient (DSC)**, reported per 3D volume.

The reported cyst-segmentation numbers established an early fully automatic baseline: **60.46 ± 31.37** DSC without deep supervision, **63.44 ± 27.71** with deep supervision, and **77.92 ± 12.83** when using a ground-truth cyst bounding box as an oracle region of interest [1706.07346]. The paper also states that the method missed **8 cyst cases** with deep supervision and **16** without it. Historically, this dataset was presented as, to the authors’ knowledge, **the largest set for pancreatic cyst segmentation** at the time.

## 3. The OCT intraretinal cyst challenge dataset often called Cyst‑X

In retinal OCT, **Cyst‑X** typically refers to the **MICCAI 2015 OPTIMA Cyst Segmentation Challenge (OCSC)** dataset [1708.06197]. Later literature explicitly equates the challenge data with **Cyst‑X** or **OPTIMA / Cyst‑X**, and describes it as the **first publicly available novel cyst segmentation challenge dataset** [2604.10843]. The dataset contains **30 OCT volumes total**, split into **15 training volumes** and **15 testing volumes**, acquired from **4 different SD‑OCT vendors**: **Cirrus**, **Nidek**, **Spectralis**, and **Topcon** [1708.06197].

The OCT resource is heterogeneous. The 2017 challenge-oriented description reports lateral resolution ranging from **\(496 \times 512\)** to **\(1024 \times 512\)** pixels and **5 to 200** B‑scans per volume [1708.06197]. Another later paper, focusing on implementation on the same challenge data, states that Spectralis examples consist of **four OCT volumes, each with 49 frames**, and that after converting all 3D volumes to 2D slices the authors obtained **1676 training images** and **909 testing images** [2604.10843]. These are not contradictory; they reflect different views of the same multi-vendor challenge corpus.

Annotation is dual-grader and pixel-wise. The challenge provides manual cyst segmentations from **Grader 1** and **Grader 2**, and different papers use different label combinations. One study trained with the **intersection** \(G1 \cap G2\) and reported performance against **G1**, **G2**, and **\(G1 \cap G2\)** [1708.06197]. Another trained on the **union** of the two graders to increase positive samples and evaluated against **Grader 1**, **Grader 2**, and the **intersection of Grader 1 & 2** [2604.10843]. This grader structure makes annotation variability part of the benchmark itself.

The dataset became a focal point for methodological progression. A domain-knowledge-assisted pipeline using TV denoising, ILM–RPE restriction, **MSER** candidates, and a **Random Forest** with **50 trees** achieved a mean Dice coefficient of **0.3893** with standard deviation **0.2987** on the training set under leave-one-out validation, with particularly weak detection for small cysts [1612.02675]. A later selective-enhancement method based on **Generalized Motion Patterns** and a CNN achieved mean Dice **0.71** on the OCSC test set in masked evaluation against \(G1 \cap G2\), outperforming published challenge participants [1708.06197]. A 2026 ResNet18 patchwise classifier on the same public challenge resource reported overall mean Dice **0.8255** against Grader 1, with vendor-level means **0.888** for Cirrus, **0.8217** for Nidek, **0.8276** for Spectralis, and **0.7639** for Topcon, alongside very high precision and reduced sensitivity on noisy Topcon scans [2604.10843].

## 4. The formal 2025 Cyst‑X multicenter pancreatic MRI dataset

The 2025 paper “**Cyst‑X: AI-Powered Pancreatic Cancer Risk Prediction from Multicenter MRI in Centralized and Federated Learning**” introduced the first resource in this group for which **Cyst‑X** is the formal dataset name [2507.22017]. It is described as **the first large-scale, multi-center pancreatic cysts MRI dataset**, publicly released to support IPMN malignancy prediction, pancreas segmentation, and federated learning.

Cyst‑X comprises **764 unique patients** and **1,461 total MRI volumes**, including **723 T1-weighted** and **738 T2-weighted** scans, collected from **7 institutions**: **New York University Langone Health**, **Mayo Clinic Florida**, **Northwestern University**, **Allegheny Health Network**, **Mayo Clinic Arizona**, **Istanbul University, Istanbul Faculty of Medicine**, and **Erasmus Medical Center** [2507.22017]. The study period spans **March 2004 – June 2024**. Vendors include **GE**, **Siemens**, and **Philips**, with **1.5T** and **3T** field strengths represented.

Each scan includes the MRI volume, a **ground-truth pancreas segmentation mask**, and a **risk/malignancy label**. The label space is three-class: **no risk**, **low risk**, and **high risk**. High-risk IPMN denotes **high-grade dysplasia or worse**, including carcinoma in situ and invasive carcinoma; low-risk IPMN includes histologically confirmed low- or intermediate-grade dysplasia or lesions without progression over **\(\ge 3\) years** of follow-up; and no-risk cases are normal pancreas or benign cysts not associated with IPMN [2507.22017]. The paper emphasizes that the dataset predominantly contains images of **IPMNs (90–95%)**.

Unlike the CT and OCT resources, this MRI benchmark does **not** release cyst-only lesion masks. The segmentation task is whole-pancreas segmentation, and the primary downstream prediction task is malignancy risk classification from the pancreas ROI. The dataset is distributed in **NIfTI** format, converted from de-identified **DICOM**, and is accompanied by a code repository implementing **PanSegNet**, **Swin‑UNETR**, **DenseNet‑121**, and federated-learning baselines. The paper gives the public links `https://osf.io/74vfs/` for the dataset and `https://github.com/NUBagciLab/Cyst-X` for code [2507.22017].

The benchmark results are correspondingly broader than segmentation alone. **PanSegNet** reached Dice **\(86.81 \pm 7.30\%\)** on T1W and **\(89.62 \pm 6.38\%\)** on T2W. For binary high-risk versus not-high-risk IPMN classification, **DenseNet‑121** achieved **AUC \(78.13 \pm 2.06\%\)** on T1W and **AUC \(82.37 \pm 1.02\%\)** on T2W, exceeding the reported **Kyoto guidelines (AUC ≈ 0.75)** [2507.22017]. The same paper also showed that federated classification performed close to centralized training, whereas federated segmentation remained materially harder.

## 5. Labels, tasks, and benchmark conventions across the three usages

The three Cyst‑X usages define substantially different machine-learning problems. The commonality is cyst-centered medical imaging; the divergence lies in supervision level and endpoint.

| Resource | Supervision structure | Primary endpoint |
|---|---|---|
| Pancreatic CT | 3D pancreas mask + 3D cyst mask | Cyst segmentation DSC |
| Retinal OCT | Dual-grader pixel-wise cyst masks | Cyst segmentation Dice, precision, sensitivity |
| Pancreatic MRI | Whole-pancreas mask + scan-level risk label | Pancreas Dice; IPMN ACC/AUC |

For the CT and OCT variants, the dominant overlap metric is the **Dice-Sørensen Coefficient**,
$$
\mathrm{DSC}(\mathcal{A}, \mathcal{G}) = \frac{2|\mathcal{A}\cap\mathcal{G}|}{|\mathcal{A}|+|\mathcal{G}|},
$$
reported per 3D volume in pancreatic CT and in challenge-style slice/volume aggregates in OCT [1706.07346; 1708.06197]. OCT studies additionally report **precision** and **sensitivity**, and sometimes distinguish **masked** from **unmasked** evaluation in the central macular region [1708.06197; 2604.10843]. The MRI release broadens the evaluation vocabulary to **Dice**, **Jaccard**, **precision**, **recall**, **HD95**, **ASSD**, **ACC**, and **AUC**, reflecting its hybrid segmentation-plus-classification design [2507.22017].

This suggests that “Cyst‑X” is best understood not as a single benchmark family with one invariant protocol, but as a label applied to datasets that foreground cyst-related pathology while varying sharply in anatomical target, task formulation, and annotation granularity.

## 6. Misattributions and adjacent resources

Several cyst-related papers do **not** define a dataset called **Cyst‑X**, even when the topic might invite that assumption. The dental radiology paper “Radious” uses **“our own dataset”** from **Valiasr Hospital in Tehran**, with **963 OPG X-rays**, **514 periapical X-rays**, **3673 bitewing X-rays**, and **466** annotated images, but it explicitly does **not** introduce or mention any dataset called **Cyst‑X** [2305.06236]. Its dataset includes labels such as **radicular cyst**, **periapical cyst**, and **cyst**, but remains unnamed and private.

Similarly, the kidney organoid video paper on **Organoid Tracker** does **not** introduce a dataset called **Cyst‑X**. It presents an analysis platform and demonstrates it on **one PKD mutant video** and **one wild-type video**, with a **7-frame time-lapse bright-field microscopy video** used in the case study, but no named external benchmark is released under that title [2509.11063]. The breast spectral mammography study on cyst fluid attenuation also does **not** define a formal dataset named **Cyst‑X**; it reports measurements on **50 breast cyst fluid samples** and **50 water samples**, which function more as a well-characterized measurement cohort than a packaged public dataset [2101.02762].

A recurring misconception, therefore, is to treat **Cyst‑X** as a generic shorthand for any cyst-imaging collection. The literature here does not support that usage. In practice, the term refers either to the later-named pancreatic CT set, to the OCT OPTIMA challenge corpus, or to the formal 2025 multicenter pancreatic MRI release; outside those contexts, it should be regarded as a misattribution unless a paper states otherwise [1706.07346; 1708.06197; 2507.22017].

Source: https://www.emergentmind.com/topics/cyst-x-dataset